Effects of pegylated interferon α on fibrinolytic parameters in patients with chronic hepatitis C.
Interferon (IFN) interacts with endothelial cells and modulates the functions of these cells. In our study, we aimed to determine the effects of treatment with pegylated IFN-α (peg-IFN-α) on fibrinolytic parameters in patients with chronic hepatitis C. Fifteen patients with chronic hepatitis C were treated with peg-IFN-α once per week plus daily oral ribavirin. Euglobulin lysis time (ELT), plasma levels of D-dimer, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI) were determined before treatment, 2 weeks, 1 month, and 3 months after the initiation of the treatment. Plasma levels of t-PA increased significantly 1 month and 3 months after the treatment (P < .05). The PAI-1 and TAFI levels in 2 weeks, 1 month and 3 months after treatment were not statistically different as compared with pretreatment levels (P > .05) No significant difference in plasma D-dimer levels was observed during peg-IFN-α treatment (P > .05). There was a significant decrease in ELT 1 month and 3 months after the treatment (P < .05). Our results indicated that treatment with peg-IFN-α may be associated with enhanced fibrinolysis.
Gokmen
Ayla
A
Division of Hematology, Department of Internal Medicine, Karaelmas University, Faculty of Medicine, Zonguldak, Turkey. ayla.akoz@hotmail.com
Ustundag
Yucel
Y
Oztoprak
Nefise
N
Aydemir
Selim
S
Tekin
Ishak Ozel
IO
Cakal
Basak
B
Kiran
Sibel
S
Engin
Huseyin
H
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage*; D025901:Carboxypeptidase B2 / Q000097:blood; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D012254:Ribavirin / Q000008:administration & dosage; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000097:blood
D000998:Antiviral Agents; D005338:Fibrin Fibrinogen Degradation Products; D016898:Interferon-alpha; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; C036309:fibrin fragment D; D012254:Ribavirin; D025901:Carboxypeptidase B2; D010959:Tissue Plasminogen Activator